These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 28322904)

  • 1. Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.
    Drake MJ; MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Herschorn S; Huang M; Stoelzel M; Siddiqui E
    Urology; 2017 Jun; 104():1-4. PubMed ID: 28322904
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictors of non-persistence in women with overactive bladder syndrome.
    Hsiao SM
    Sci Rep; 2024 Mar; 14(1):7499. PubMed ID: 38553529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons learned from a multi-data source research collaboration: The mirabegron post-authorization safety study program.
    de Vogel S; Seeger JD; Arana A; Margulis AV; McQuay LJ; Perez-Gutthann S; Hallas J; Kristiansen NS; Linder M; Odsbu I; Suehs B; Xu Y; Uribe C; Appenteng K; Robinson NJ
    Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5799. PubMed ID: 38680102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorimetric study on a novel FDA-approved combination used for the treatment of overactive bladder syndrome in different matrices.
    Nour IM; Mohamed AR; Hasan MA; Badrawy M
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 Feb; 307():123644. PubMed ID: 37976575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
    Drake MJ; MacDiarmid S; Chapple CR; Esen A; Athanasiou S; Cambronero Santos J; Mitcheson D; Herschorn S; Siddiqui E; Huang M; Stoelzel M
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28419650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
    Robinson D; Kelleher C; Staskin D; Mueller ER; Falconer C; Wang J; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Hakimi Z; Herschorn S
    Neurourol Urodyn; 2018 Jan; 37(1):394-406. PubMed ID: 28704584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
    Staskin D; Herschorn S; Fialkov J; Tu LM; Walsh T; Schermer CR
    Int Urogynecol J; 2018 Feb; 29(2):273-283. PubMed ID: 28620791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.
    Tubaro A; Batista JE; Nitti VW; Herschorn S; Chapple CR; Blauwet MB; Siddiqui E; Huang M; Oelke M
    Ther Adv Urol; 2017 Dec; 9(6):137-154. PubMed ID: 28588652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.
    Sussman D; Yehoshua A; Kowalski J; Lee W; Kish J; Chaudhari S; Murray B
    Int J Clin Pract; 2017 Mar; 71(3-4):. PubMed ID: 28371019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
    Bunniran S; Davis C; Kristy R; Ng D; Schermer CR; Uribe C; Suehs BT
    Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
    Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
    Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New data on the combined treatment of solifenacin and mirabegron in patients with overactive bladder: SYNERGY study.
    Alcántara Montero A
    Actas Urol Esp (Engl Ed); 2018; 42(1):70-71. PubMed ID: 28595987
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder.
    Newgreen D; Bosman B; Hollestein-Havelaar A; Dahler E; Besuyen R; Snijder R; Sawyer W; Rittig S; Bolduc S
    J Urol; 2017 Oct; 198(4):928-936. PubMed ID: 28506854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias.
    Kaye JA; Margulis AV; Fortuny J; McQuay LJ; Plana E; Bartsch JL; Bui CL; Perez-Gutthann S; Arana A
    Pharmacotherapy; 2017 Jun; 37(6):673-683. PubMed ID: 28370075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could Reduced Fluid Intake Cause the Placebo Effect Seen in Overactive Bladder Clinical Trials? Analysis of a Large Solifenacin Integrated Database.
    Herschorn S; Chapple CR; Snijder R; Siddiqui E; Cardozo L
    Urology; 2017 Aug; 106():55-59. PubMed ID: 28435033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the Site and Mechanism of Action of β
    Andersson KE
    Int Neurourol J; 2017 Mar; 21(1):6-11. PubMed ID: 28361520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better Persistence Rates with Mirabegron: Questions Raised.
    Wein AJ
    Eur Urol; 2017 Sep; 72(3):400-401. PubMed ID: 28400166
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
    Kato D; Tabuchi H; Uno S
    Low Urin Tract Symptoms; 2019 Jan; 11(1):14-23. PubMed ID: 28762672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis.
    Drake MJ; Nitti VW; Ginsberg DA; Brucker BM; Hepp Z; McCool R; Glanville JM; Fleetwood K; James D; Chapple CR
    BJU Int; 2017 Nov; 120(5):611-622. PubMed ID: 28670786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.